Dr. Dummer on COMBI-AD Trial Results in BRAF-Mutant Melanoma

Reinhard Dummer, MD
Published: Tuesday, Sep 12, 2017



Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

This is a prospective randomized placebo-controlled trial of 900 enrolled patients who had previously undergone complete resection of all metastatic disease. They were then randomized to receive the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) or placebo. The treatment duration was 1 year and the primary endpoint was relapse-free survival (RFS).

There was a clear advantage for the combination over placebo, Dummer explains. The hazard ratio was below 0.5. Other endpoints, aside from RFS, were positive, including distant metastases-free survival and overall survival.  

<<< View more from the 2017 ESMO Congress


Reinhard Dummer, MD, of University Hospital Zurich, discusses the results of the phase III COMBI-AD study presented at the 2017 ESMO Congress in patients with stage III BRAF-mutant melanoma.

This is a prospective randomized placebo-controlled trial of 900 enrolled patients who had previously undergone complete resection of all metastatic disease. They were then randomized to receive the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) or placebo. The treatment duration was 1 year and the primary endpoint was relapse-free survival (RFS).

There was a clear advantage for the combination over placebo, Dummer explains. The hazard ratio was below 0.5. Other endpoints, aside from RFS, were positive, including distant metastases-free survival and overall survival.  

<<< View more from the 2017 ESMO Congress

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Medical Crossfire®: What Does Data Tell Us About How to Optimize Checkpoint Inhibitor Strategies Across Lines of Care for Patients with Melanoma?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x